Practice & Background

Jingli Jiang is an associate in Akin Gump’s Beijing office. Ms. Jiang’s practice focuses on China outbound and inbound mergers and acquisitions, PE/VC investment, other cross-border transactions and compliance matters such as antitrust and trade policy. Prior to joining Akin Gump in 2014, Ms. Jiang worked for a major multinational company’s investment platform. She has worked on a number of high-profile international transactions in Greater China, South Asia, Australia and South America. She got her JD degree from the University of Texas School of Law.

Representative Matters

Ms. Jiang’s recent major engagements include advising:

  • a Middle East investment fund in its Series A financing of a Chinese technology company
  • a major Chinese private equity fund in its proposed equity investment in a NYSE listed oil and gas company
  • a Middle East investment fund in its investment to a pre-IPO Chinese technology company
  • a major state-owned Chinese power company in its proposed equity transaction in Indonesia
  • Lukoil in its divestment of its upstream assets in Kazakhstan
  • China Development Bank and China Grand Pharmaceutical in their joint acquisition of a German medical device company
  • a Chinese financial institute in a commercial lending transaction with a Cayman registered real estate company
  • a Chinese state-owned manufacturing company in a technical licensing and commercial lending transaction with a U.S. manufacturing company
  • a U.S. venture capital in its formation of a joint venture in China and proposed equity investment in a U.S. listed Chinese company
  • a foreign listed education service company in its potential acquisition of a Chinese company through VIE structure
  • Sequoia Capital in its Series A financing of a startup Chinese technology company
  • a Cayman company in its fund raising through private placement in China
  • a major state-owned Chinese power company in its proposed acquisition of an Indonesia coal and power company
  • a state-owned investment fund in its acquisition of a German medical device company

Languages

English
Mandarin